The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Triapin 2.5mg/2.5mg prolonged release tablet

2.5 mg/2.5 milligram(s) Prolonged-release tablet

Sanofi-Aventis Ireland Limited T/A SANOFIPA0540/082/001

Main Information

Trade NameTriapin 2.5mg/2.5mg prolonged release tablet
Active SubstancesFelodipine
Ramipril
Strength2.5 mg/2.5 milligram(s)
Dosage FormProlonged-release tablet
Licence HolderSanofi-Aventis Ireland Limited T/A SANOFI
Licence NumberPA0540/082/001

Group Information

ATC CodeC09BB ACE inhibitors and calcium channel blockers
C09BB05 ramipril and felodipine

Status

Authorised/WithdrawnAuthorised
Licence Issued13/07/1998
Legal statusProduct subject to prescription which may be renewed (B)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusMarketed

Documents

Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available

Generics Information

Interchangeable List CodeIC0032-052-024
Interchangeable List DocumentPDF of Interchangeable List
« Back